Risk talk:: rhetorical strategies in consultations on hormone replacement therapy

被引:11
|
作者
Hoffmann, M
Linell, P
Lindh-Åstrand, L
Kjellgren, KI
机构
[1] Linkoping Univ, Dept Med & Care, Div Clin Pharmacol, SE-58183 Linkoping, Sweden
[2] Linkoping Univ, Dept Commun Studies, SE-58183 Linkoping, Sweden
[3] Linkoping Univ, Dept Mol & Clin Med, Div Obstet & Gynecol, SE-58183 Linkoping, Sweden
[4] Gothenburg Univ, Sahlgrenska Acad, Fac Hlth & Caring Sci, Inst Nursing, SE-40530 Gothenburg, Sweden
关键词
risk; communication; menopause; hormone replacement therapy; physician-patient relations;
D O I
10.1080/1369857031000123920
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
When analysing risk discussions in medical settings it is important to consider the specific activity type. In this qualitative study 20 first-time consultations by healthy women regarding hormone replacement therapy (HRT) in the menopause the risk discussion is asymmetrical with the doctors dominating. Despite being set up as a specific opportunity for women in the menopause to discuss problems and risks, it comes forth as a decision-making activity in a traditional medical setting. The consultations fulfil to a high extent the demands for informed decision making, but the risk discussions are recontextualised into a cost-benefit discourse with a typical implicit quantitative bias. The doctors use several different rhetorical strategies such as positive introduction of HRT, embedding drawbacks in positive introductions and/or exits thereby diminishing them. The word risk is avoided to a considerable extent and the term 'drawbacks' is used instead. The most obvious strategy is to move from the woman's symptoms to aspects of prevention, thus changing the discussion from the menopause and different strategies to cope with menopausal problems into a medically oriented discussion of pharmacological treatment alternatives. The 'change of life' in these talks is entirely conceptualised within a 'medical model'.
引用
收藏
页码:139 / 154
页数:16
相关论文
共 50 条
  • [31] Hormone replacement therapy and breast cancer risk in a nationally representative cohort
    Lando, JF
    Heck, KE
    Brett, KM
    AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 1999, 17 (03) : 176 - 180
  • [32] Hormone replacement therapy in menopause as a risk factor for developing breast cancer
    Souto, Natasha Firmino
    Moreira, Camila Brasil
    Soares Barros, Paulo Augusto
    Carvalho Fernandes, Ana Fatima
    Lavinas Santos, Miria Conceicao
    REVISTA DE PESQUISA-CUIDADO E FUNDAMENTAL ONLINE, 2014, 6 (03): : 1302 - 1312
  • [33] Perspectives in hormone replacement therapy
    Kenemans, P
    van Unnik, GA
    Mijatovic, V
    van der Mooren, MJ
    MATURITAS, 2001, 38 : S41 - S48
  • [34] Intranasal hormone replacement therapy
    Wattanakumtornkul, S
    Pinto, AB
    Williams, DB
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2003, 10 (01): : 88 - 98
  • [35] Hormone replacement therapy and thrombotic risk: beauty is only skin deep
    Rosendaal, Frits R.
    NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2008, 5 (11): : 684 - 685
  • [36] Women's views of optimal risk communication and decision making in general practice consultations about the menopause and hormone replacement therapy
    Walter, FM
    Emery, JD
    Rogers, M
    Britten, N
    PATIENT EDUCATION AND COUNSELING, 2004, 53 (02) : 121 - 128
  • [37] The effects of estrogen and hormone replacement therapy on cardiovascular systems
    Hashemzadeh, Mehrnoosh
    Romo, Ryan
    Arreguin, Joseph M.
    Movahed, Mohammed Reza
    FUTURE CARDIOLOGY, 2020, 17 (02) : 347 - 353
  • [38] The mechanisms of thrombotic risk induced by hormone replacement therapy
    Cano, A
    Van Baal, WM
    MATURITAS, 2001, 40 (01) : 17 - 38
  • [39] Hormone replacement therapy and lung cancer risk in Chinese
    Chen, Kuan-Yu
    Hsiao, Chin-Fu
    Chang, Gee-Chen
    Tsai, Yin-Huang
    Su, Wu-Chou
    Perng, Reury-Perng
    Huang, Ming-Shyan
    Hsiung, Chao A.
    Chen, Chien-Jen
    Yang, Pan-Chyr
    CANCER, 2007, 110 (08) : 1768 - 1775
  • [40] Transformation or replacement - Effects of hormone therapy on cardiovascular risk
    Kielb, Julia
    Weber, Jessica
    Baensch, Leonard
    Shahjerdi, Khatereh
    Celik, Aylin
    Farahat, Nora
    Riek, Sally
    Chavez-Talavera, Oscar
    Grandoch, Maria
    Polzin, Amin
    Kelm, Malte
    Dannenberg, Lisa
    PHARMACOLOGY & THERAPEUTICS, 2024, 254